There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Verona Pharma (VRNA) and Rhythm Pharmaceuticals (RYTM) with bullish sentiments.
Verona Pharma (VRNA)
Wedbush analyst Liana Moussatos reiterated a Buy rating on Verona Pharma today and set a price target of $25.00. The company’s shares closed last Friday at $7.25.
According to TipRanks.com, Moussatos is a 4-star analyst with an average return of 10.4% and a 52.8% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Catabasis Pharmaceuticals, and Eiger Biopharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Verona Pharma with a $25.00 average price target.
See today’s analyst top recommended stocks >>
Rhythm Pharmaceuticals (RYTM)
In a report released today, Alan Carr from Needham assigned a Buy rating to Rhythm Pharmaceuticals, with a price target of $42.00. The company’s shares closed last Friday at $29.27, close to its 52-week high of $32.24.
According to TipRanks.com, Carr is a 4-star analyst with an average return of 6.4% and a 47.1% success rate. Carr covers the Healthcare sector, focusing on stocks such as Lexicon Pharmaceuticals, Phathom Pharmaceuticals, and Crispr Therapeutics AG.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Rhythm Pharmaceuticals with a $37.83 average price target, representing a 39.0% upside. In a report issued on November 27, Stifel Nicolaus also reiterated a Buy rating on the stock with a $37.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on RYTM:
